BlackRock, Inc. 13D and 13G filings for Eagle Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-07-08 4:32 pm Sale |
2024-06-30 | 13G | Eagle Pharmaceuticals, Inc. EGRX |
BlackRock Inc. BLK |
351,570 2.700% |
-632,505 (-64.27%) |
Filing |
| 2024-01-26 11:49 am Sale |
2023-12-31 | 13G | Eagle Pharmaceuticals, Inc. EGRX |
BlackRock Inc. BLK |
984,075 7.600% |
-25,015 (-2.48%) |
Filing |
| 2023-07-07 4:35 pm Sale |
2023-06-30 | 13G | Eagle Pharmaceuticals, Inc. EGRX |
BlackRock Inc. BLK |
1,009,090 7.700% |
-863,811 (-46.12%) |
Filing |
| 2023-01-26 08:52 am Unchanged |
2022-12-31 | 13G | Eagle Pharmaceuticals, Inc. EGRX |
BlackRock Inc. BLK |
1,872,901 14.400% |
0 (Unchanged) |
Filing |
| 2023-01-20 3:00 pm Sale |
2022-12-31 | 13G | Eagle Pharmaceuticals, Inc. EGRX |
BlackRock Inc. BLK |
1,872,901 14.400% |
-95,915 (-4.87%) |
Filing |
| 2022-01-27 11:00 am Unchanged |
2021-12-31 | 13G | Eagle Pharmaceuticals, Inc. EGRX |
BlackRock Inc. BLK |
1,968,816 15.200% |
0 (Unchanged) |
Filing |
| 2022-01-25 3:03 pm Purchase |
2021-12-31 | 13G | Eagle Pharmaceuticals, Inc. EGRX |
BlackRock Inc. BLK |
1,968,816 15.200% |
27,800 (+1.43%) |
Filing |
| 2021-01-26 2:22 pm Purchase |
2020-12-31 | 13G | Eagle Pharmaceuticals, Inc. EGRX |
BlackRock Inc. BLK |
1,941,016 14.900% |
132,504 (+7.33%) |
Filing |